- Home
- GERN vs RLX Comparison
GERN vs RLX Comparison
Compare GERN & RLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- RLX
- Stock Information
- Founded
- GERN 1990
- RLX 2018
- Country
- GERN United States
- RLX China
- Employees
- GERN N/A
- RLX N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- RLX Medicinal Chemicals and Botanical Products
- Sector
- GERN Health Care
- RLX Health Care
- Exchange
- GERN Nasdaq
- RLX Nasdaq
- Market Cap
- GERN 2.5B
- RLX 3.1B
- IPO Year
- GERN 1996
- RLX 2021
- Fundamental
- Price
- GERN $3.34
- RLX $2.00
- Analyst Decision
- GERN Strong Buy
- RLX Strong Buy
- Analyst Count
- GERN 10
- RLX 1
- Target Price
- GERN $7.05
- RLX $2.76
- AVG Volume (30 Days)
- GERN 8.0M
- RLX 5.8M
- Earning Date
- GERN 11-07-2024
- RLX 11-15-2024
- Dividend Yield
- GERN N/A
- RLX 0.50%
- EPS Growth
- GERN N/A
- RLX 607.62
- EPS
- GERN N/A
- RLX 0.07
- Revenue
- GERN $29,480,000.00
- RLX $307,798,132.00
- Revenue This Year
- GERN $32,021.10
- RLX $116.31
- Revenue Next Year
- GERN $298.14
- RLX $46.01
- P/E Ratio
- GERN N/A
- RLX $28.35
- Revenue Growth
- GERN 9199.68
- RLX 99.79
- 52 Week Low
- GERN $1.64
- RLX $1.50
- 52 Week High
- GERN $5.34
- RLX $2.19
- Technical
- Relative Strength Index (RSI)
- GERN 25.88
- RLX 61.48
- Support Level
- GERN $3.75
- RLX $1.94
- Resistance Level
- GERN $4.00
- RLX $2.08
- Average True Range (ATR)
- GERN 0.17
- RLX 0.07
- MACD
- GERN -0.06
- RLX -0.00
- Stochastic Oscillator
- GERN 7.41
- RLX 68.97
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.